PROJECT DETAILS
Therapeutic Area
Oncology
Payment Model
Oncology Care Model (CMMI)
Analysis Type
6-Month Episode
Capabilities
RWE, Actuarial Modeling, HEOR
HEOR
Value-Based Care
Oncology
Enhancing Market Access for Oncology Drug Under OCM
A data-driven strategy leveraging real-world evidence, actuarial modeling, and HEOR analytics to optimize drug positioning within the Oncology Care Model's episode-based payment structure.
💹
Value-Based Care Strategy
✓
Provider Adoption
Multi
Scenario Modeling
RWE
Data-Driven
6mo
Episode Analysis
the challenge
Navigating Episode-Based Payment Complexity
The Oncology Care Model (OCM) created a challenging reimbursement environment for high-cost oncology drugs. The model's two-part payment structure Monthly Enhanced Oncology Services (MEOS) payments plus performance-based payments (PBP) tied to total cost of care benchmarks created financial disincentives for expensive therapies.
Providers under OCM were under intense pressure to manage total episode costs. Without compelling economic evidence tailored to OCM's episode-based framework, the oncology drug was losing ground to lower-cost alternatives.
"Comparing the drug against lower-cost alternatives was challenging due to limited direct trial comparisons and a lack of comprehensive economic modeling for payer decision-making."
Our Approach
RWE-Driven Episode Cost Analysis
We developed a rigorous, multi-pronged strategy combining real-world evidence analysis with actuarial modeling to demonstrate the drug's economic viability within OCM.
01
Real-World Evidence Analysis
Conducted retrospective analysis using commercially available RWE datasets to quantify drug utilization patterns in OCM vs. non-OCM practices.
02
Episode Cost Mapping
Mapped full episode costs including hospitalizations, ER visits, and supportive care to identify where the drug created cost offsets.
03
Actuarial Modeling
Built multi-scenario models estimating financial impact within 6-month OCM episodes, accounting for adverse event reductions and hospitalization offsets.
04
Provider Economics Alignment
Tailored messaging and tools for field teams to communicate value in OCM-specific financial terms that resonated with practice administrators.
"
This project ensured that the drug remained a viable option within OCM-participating practices, driving both clinical adoption and financial sustainability in a challenging reimbursement landscape.
Engagement Outcome
the results
Economic Viability Demonstrated
The analysis successfully demonstrated the drug's economic viability within OCM by quantifying cost offsets and total episode impact.
💼
Equipped
Field teams with OCM-specific value messaging
📊
Proven
Cost offsets quantified within OCM episode framework
🏥
Maintained
Provider adoption at OCM-participating practices
key insights
Lessons for Value-Based Care
1
Episode Framing Is Essential
Value arguments must be translated into episode-based terms that align with how OCM practices measure financial performance.
2
RWE Enables Credible Analysis
Real-world evidence provides the data foundation needed to demonstrate cost offsets when trial data alone is insufficient.
3
Multi-Scenario Modeling Builds Confidence
Presenting multiple scenarios with sensitivity analyses addresses administrator concerns about financial risk.
4
Field Team Enablement Is Critical
Even the best analysis fails without practical tools that field teams can use in real conversations with practice administrators.
Navigating Value-Based Care Models?
Let's discuss how to demonstrate value in episode-based payment models and alternative payment arrangements.